Alector Obtains $29,500,000 Series D Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    953 Indiana Street San Francisco, CA 94107 USA
  • Company Description
    Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series D
  • Proceeds Purposes
    These significant financial resources provide Alector the ability to independently advance its promising drug candidates into the clinic and expand our discovery pipeline of candidates for neurodegenerative disorders.
  • M&A Terms
  • Venture Investor
    Dementia Discovery Fund
  • Venture Investor
    Amgen Ventures
  • Venture Investor
    AbbVie Biotech Ventures
  • Venture Investor
    Merck Capital Ventures
  • Venture Investor
  • Venture Investor
    Polaris Partners
  • Venture Investor
  • Venture Investor
    Topspin Partners
  • Venture Investor
    Mission Bay Capital

Trending on Xconomy